ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 11.18 USD -1.24%
Market Cap: 1.1B USD
Have any thoughts about
ARS Pharmaceuticals Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

-14.6
Current
-9.1
Median
4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-14.6
=
Enterprise Value
881.5m USD
/
EBIT
-60.5m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
US
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Average EV/EBIT: 21.3
Negative Multiple: -14.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.5
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.8 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-14.7
2-Years Forward
EV/EBIT
-16.7
3-Years Forward
EV/EBIT
326.5

See Also

Discover More